Title: The Role of Organoids in Understanding and Treating Infectious Diseases
Key to the development of the HUB Organoid Technology was the discovery of LGR5+ intestinal adult stem cells by the Clevers lab. When provided with the appropriate growth factors, HUB Organoids proved to be both genetically and phenotypically stable during prolonged periods of cell culture and are amenable to all standard experimental manipulations, including middle through-put drug screen.
Because HUB Organoids can be generated from normal/healthy tissue and they maintain individual and tissue-specific characteristics, they have the potential to model viral infection diseases with relevant clinical implications such as Hepatitis B (HBV), Respiratory Syncytial (RSV) and more recently Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2). At the same time, HUB Organoids can be used as a relevant patient model in (pre-)clinical phases to test effective drug treatments for infectious diseases, from which a relevant patient model was not available before.
Speaker: Sylvia F. Boj
Date: June 18
Time: 5 PM CET
Register now: Organoids Master Class Webinar Series Sylvia Boj